AbbVie Inc (ABBV)vsDoximity Inc (DOCS)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
DOCS
Doximity Inc
$20.59
-0.53%
HEALTHCARE · Cap: $3.66B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9641% more annual revenue ($62.82B vs $644.86M). DOCS leads profitability with a 30.4% profit margin vs 5.8%. DOCS appears more attractively valued with a PEG of 0.59. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
DOCS
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+49.8%
Fair Value
$51.73
Current Price
$20.59
$31.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Keeps 30 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Strong operational efficiency at 21.6%
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Weak financial health signals
Earnings declined 69.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : DOCS
The strongest argument for DOCS centers on Profit Margin, Debt/Equity, Return on Equity. Profitability is solid with margins at 30.4% and operating margin at 21.6%. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : DOCS
The primary concerns for DOCS are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while DOCS is a mature play — different risk/reward profiles.
DOCS carries more volatility with a beta of 1.29 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 62/100) and 12.4% revenue growth. DOCS offers better value entry with a 49.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Doximity Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?